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Abstract
Objective: To investigate the relationship between hormone replacement therapy (HRT) and performance on the 
Wechsler Memory Scale-III (WMS-III) after controlling for confounders, and to determine the impact of different types 
of HRT and the effect of APOE ε4 allele status on memory performance.
Methods: A sample of 223 postmenopausal women aged 44-80 years enrolled in the Longitudinal Assessment of 
Women (LAW) study participated in this study. Participants were administered tests of verbal memory, auditory mem-
ory, visual memory, attention and working memory from the WMS-III. Information on their HRT use, and a range of 
demographic and health variables were also collected.
Results: After controlling for covariates, HRT use contributed unique variance to performance on the Spatial Span sub-
test of the WMS-III and estrogen-only users performed more poorly on this task than nonusers. APOE ε4 contributed 
unique variance to the Letter-Number Sequencing Subtest of the WMS-III. No significant HRT use by APOE interaction 
was found. 
Conclusion: In summary, HRT use was observed to have minimum effect overall on the performance of postmen-
opausal women on the WMS-III.  The APOE ε4 allele was also demonstrated to have minimal influence on cognitive 
functioning, and it did not interact significantly with HRT to affect test performance.
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Introduction
Several studies have suggested that estrogen affects cogni-
tive functions, and that verbal memory functioning may be 
particularly sensitive to positive effects of estrogen in per-
imenopausal and/or postmenopausal women [1-3]. It was 
posited that estrogen affects brain function by influencing 
the cholinergic system in both the basal forebrain and its 
hippocampal afferents, thereby enhancing hippocam-
pal-dependent learning and memory behavior [4]. Yet, a 
meta-analysis found no consistent relationship between 
hormone replacement therapy (HRT) and cognitive per-
formance, where most of the positive effects were reported 
by cross-sectional studies and no effects or even negative 
effects being reported by longitudinal studies or random-
ized-controlled trials [5]. 
There are a number of explanations for these discrep-
ancies, including pre-existing differences between HRT 
users and non-users, the age at which HRT is commenced 
and the type of HRT. It has been demonstrated that HRT 
users are generally better educated and of higher socioeco-
nomic status, which may be linked with better cognitive 
functioning and possibly greater access to medical ser-
vices and healthier lifestyles (the “healthy user bias”) [6, 7]. 
HRT users have better controlled blood pressure, healthier 
weight range, engagement in exercise and moderate alco-
hol consumption [8]. HRT users may also be less inclined 
to suffer from depressed mood, perhaps due to a reduction 
in climacteric symptoms or positive effects of estrogen on 
serotonergic transmission [9], which may translate to bet-
ter cognitive performance. 
In previous research on HRT and cognitive function-
ing, many researchers have failed to acknowledge that pro-
gesterone may also affect cognition and tend to combine 
users of estrogen and users of combined estrogen and pro-
gesterone therapy into a “HRT users” group in their anal-
yses [e.g. 10, 11]. It has been shown in animal studies that 
adding progesterone may reverse some of the beneficial 
effects of estrogen on neural functioning [12]. Moreover, 
women on combined estrogen and progesterone commit-
ted more overall errors and more perseverative errors on 
a measure of executive function, as well as poorer perfor-
mance on a task assessing source memory compared to es-
trogen users [13], suggesting a deleterious effect of proges-
terone on cognitive function.
While the variables of age, education, general intellectual 
functioning, mood, climacteric symptoms, socioeconomic 
status, and attention have been demonstrated to influence 
cognitive performance [14], the apolipoprotein E (APOE) 
ε4 allele has also been linked to increased cognitive 
decline in the Mini Mental State Examination (MMSE), 
immediate and delayed verbal recall in some studies 
[e.g. 15, 16] though not all [e.g. 17]. Small, Rosnick, 
Fratiglioni, and Backman [18] conducted a meta-analysis 
of 38 cross-sectional studies with over 20,000 participants 
concerning the presence and magnitude of ε4-related 
cognitive deficits. Results indicated significant APOE 
-ε4 group differences for global cognitive functioning, 
episodic memory, and executive functioning, in favor of 
non-ε4 carriers. However, no differences were observed 
for primary memory, attention, visuospatial skill, verbal 
ability, and perceptual speed. Furthermore, older age and 
APOE ε4 heterozygosity was associated with smaller ε4-
related impairments. This pattern of results mirrors the 
relationship between APOE ε4 and the risk of Alzheimer’s 
Disease (AD), whereby the ε4 allele is less relevant as a risk 
factor for AD with advancing age [19], as well as studies 
which have observed greater deficits among APOE ε4 
homozygotes in cognitive performance [20]. The meta-
analysis results suggested that APOE ε4 genotype does 
affect cognitive performance in healthy aging, although the 
influence is relatively small and specific to certain domains 
of cognitive performance. 
The effect of the APOE ε4 allele on the relationship 
between HRT use and memory functioning has been un-
clear and inconsistent. Jacobs et al. [21] reported signif-
icant benefits of estrogen-replacement use on cognitive 
functioning, irrespective of APOE genotype, whereas 
Geerlings et al. [22] reported longer estrogen exposure 
to be associated with a higher risk of dementia, with the 
risk most pronounced in women with at least one APOE 
ε4 allele. Burkhardt et al. [23] produced different findings 
yet again, reporting that estrogen-only users who were 
non-ε4 bearers showed the best performance on a measure 
of episodic learning and memory, while ε4 bearers who 
were using estrogen only therapy showed no advantage 
in performance over the ε4 bearers who were not taking 
estrogen therapy. 
The aim of this paper is to clarify the relationship be-
tween hormone HRT and memory performances using the 
Wechsler Memory Scale-III (WMS-III) after controlling 
for confounders, and to determine the impact of different 
types of HRT and the effect of APOE ε4 allele status on 
memory performance.
Methods
Participants
Data were derived from the baseline data collected in the 
Longitudinal Assessment of Women (LAW) study which 
commenced in 2001 in Brisbane. The LAW study is a pop-
ulation-based study of urban women aged 40-79 years at 
inception. Details of the study were described elsewhere 
[24, 25]. Ethics approval for the study was granted by the 
Human Research Ethics Committees of the Royal Brisbane 
and Women’s Hospital (RBWH) and the University of 
Queensland, Australia. All participants provided written 
informed consent prior to commencement in the study.
Procedure
Participants visited the RBWH to complete various com-
ponents of the study according to a standard protocol. Data 
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on employment status, marital status, occupation, socio-
economic status, annual household income, menopause 
status and age at menopause, previous oral contraceptive 
use, medication use, activity level, smoking, drinking [Al-
cohol Use Disorder Identification Test, AUDIT: 26], cli-
macteric symptoms [Greene Climacteric Scale, GCS: 27] 
and mood symptoms [General Health Questionnaire-30, 
GHQ-30: 28, 29] were obtained. Clinic blood pressure 
was measured by registered nurses with participants seat-
ed. Body mass index was calculated from measurements 
of height and weight using a standard stadiometer and a 
weight scale and hip-to-waist ratio was derived from mea-
surements of hip and waist circumference using a measur-
ing tape. Fasting basal metabolic rate (BMR) was measured 
in kilojoules per minute by gas analysis using a portable 
respirometer with fasting. Genotyping for APOE risk was 
classified as ε4 allele bearers (considered at increased risk 
of dementia, consisting of those with 2/4, 3/4 and 4/4 geno-
types) and nonbearers (considered at no increased risk of 
dementia, consisting of 2/2, 3/3 and 2/3 genotypes). Neuro-
psychological tests were conducted by two registered psy-
chologists in a standardized manner. 
Measures
The Wechsler Memory Scale-III (WMS-III) is a standard-
ized individually administered battery of subtests that as-
sess learning and memory functions in adults, aged 16-89 
years [30]. Raw scores from all 12 subtests, measuring im-
mediate and delayed visual and verbal memory, attention/
working memory as well as recognition memory were 
used in the analyses. Eight memory indices were also cal-
culated by adding the appropriate age-standardized scaled 
scores of the 12 subtests with a mean of 100 and standard 
deviation of 15. 
National Adult Reading Test [NART; 31] is a single-
word reading test to estimate premorbid intelligence.
The Greene Climacteric Scale [GCS; 27] is a 21-item 
questionnaire assessing core climacteric symptoms (e.g. 
crying spells, feeling dizzy or faint, hot flushes) on a 
4-point Likert scale, ranging from Not at all to Extremely. 
Factor analysis indicated that the three symptom clusters 
that consistently emerged represent Vasomotor, Somat-
ic, and Psychological factors, with the latter factor also 
sub-divided into two further factors representing Anxiety 
and Depression. An additional symptom (Sexual Interest), 
pertaining to loss of sexual interest, was also added with 
the intention of eliciting whether further sensitive evalua-
tion of difficulties in this area is necessary [27].  
The General Health Questionnaire-30 item (GHQ-30); 
is a self-administered screening measure designed to detect 
psychiatric disorders among respondents in community 
settings [28, 29]. Respondents rated themselves on how 
they had been feeling over the past month on a 4-point se-
verity scale (Better than usual; Same as usual; Worse than 
usual; and Much worse than usual). 
Statistical Analyses
All statistical analyses were undertaken using SPSS version 
10.0 for Windows. For all analyses, the sample size was suf-
ficient to obtain at least a medium effect size with power 
of 80% [32], except where indicated otherwise. A series of 
independent sample t-tests and chi-square tests were per-
formed comparing the characteristics of HRT users and 
non-users.
Separate hierarchical regressions were conducted to 
determine the impact of HRT on each of the WMS-III 
subtests and index scores. To control for the possible con-
founding variables, including age, education, premorbid 
intellectual functioning (NART predicted Full Scale In-
telligence Quotient (FSIQ)), climacteric symptoms (GCS 
score), mood (GHQ-30 score), socioeconomic status (SES), 
APOE genotype, and use of psychiatric medications were 
entered into the regression together at step 1 and HRT use 
was entered at step 2.  The same procedure was used for 
analysis of the WMS-III index scores, with the exception of 
age as it was accounted for in the standardized index scores. 
Listwise deletion was used for those participants with miss-
ing data for any of the categorical variables.  The α level 
was set at 0.05 and Bonferroni corrections were not used as 
many of the variables are highly dependent on one another 
and applying the correction would increase the likelihood 
of Type II errors. 
The same procedure was repeated for the evaluation of 
the effect of APOE genotype on the WMS-III, using the 
same covariates as above, with the following exception: 
HRT use was found to be a significant predictor of Spatial 
Span performance in previous analyses therefore it was en-
tered at Step 1 for the analysis of Spatial Span performance. 
APOE genotype (presence or absence of the APOE ε4 allele) 
was entered at step 2.  
A series of one-way ANCOVAs with planned compar-
isons was conducted to determine differences in WMS-III 
scores among the different HRT subtypes: estrogen-only 
replacement users and nonusers, combined estrogen and 
progesterone replacement users and the nonusers, and es-
trogen-only replacement users and combined estrogen and 
progesterone replacement users. The same control variables 
mentioned earlier were held constant by entering them into 
the analyses as covariates. Given that only three compari-
sons were conducted, and that they were selected a priori, 
no adjustment was made to the alpha level, as recommend-
ed by Keppel and Zedeck [33]. Similarly, a series of two-by-
two ANCOVAs were conducted to determine whether the 
interactions of the independent variables of HRT use and 
APOE ε4 allele genotype significantly affected performance 
on the WMS-III performance. HRT use had two levels 
(HRT use vs nonuse), as did APOE genotype (ε4 bearer 
vs non-ε4 bearer). The variables of age, education, NART 
predicted FSIQ, SES, GHQ-30 score, GCS score, and use of 
psychiatric medications (yes or no) were controlled for by 
entering them into the model as covariates. The variables 
of education and SES were entered as categorical variables.
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Results
Of the initial 511 women enrolled into the LAW study, 18 
women were excluded from this component of the study 
due to ineligibility. As only postmenopausal women were 
of interest in the current study, those classified as pre-
menopausal (n = 87) or perimenopausal (n = 28), or whose 
menopausal status was unknown (n = 22), were not includ-
ed, leaving a total of 308 women. The data set was further 
reduced to include only postmenopausal women who were 
currently taking HRT (‘HRT users’) and postmenopausal 
women who had never taken any form of HRT (‘nonus-
ers’), leaving a total of 245 women in the study.  Further 
exclusions were applied to remove those with neurologi-
cal diagnoses or other conditions that may interfere with 
performance on cognitive tests. An additional case was 
deleted due to attaining an MMSE score of less than 24 
on initial screening, suggesting potential pre-existing cog-
nitive impairment. Following these exclusions, a total of 
223 participants remained in the data set for analysis (age 
range:  44-80 years). Of these participants, 22 had under-
gone a surgical menopause (removal of both ovaries and 
uterus) while 201 had experienced a natural menopause. 
Ninety-nine of the participants were classified as current 
HRT users and 124 as nonusers.  Of the current-users, 43 
were taking HRT in the form of an estrogen-only prepara-
tion, while 56 were using a combined estrogen and proges-
terone form of HRT. Information pertaining to the dosage 
of HRT taken was not collected from all participants and 
is therefore not reported here.  The ethnicity of the par-
ticipants was predominantly Caucasian (n = 222), and one 
participant was of Indigenous Australian descent. 
Table 1. Demographic characteristics and t-tests for HRT users and nonusers
Characteristic
(Mean ± SD)
HRT users
(n = 95)
Nonusers
(n = 118) t (211)
Current age  (years) 61.39 ± 7.98 66.54 ± 8.92 4.39***
Age of final menstrual period 48.37 ± 4.96 49.61 ± 3.85 1.94
NART predicted FSIQ 105.27 ± 9.23 104.40 ± 10.86 0.62
GHQ-30 score 2.78 ± 5.55 2.14 ± 3.46 1.02
GCS 
   Vasomotor symptoms 0.62 ± 1.08 0.60 ± 1.35 -0.11
   Somatic symptoms 3.26 ± 2.34 2.89 ± 2.49 -1.12
   Psychological symptoms 5.87 ± 4.59 5.00 ± 3.86 -1.51
GCS
   Anxiety 3.25 ± 2.58 2.90 ± 2.37 -1.04
   Depression 2.62 ± 2.47 2.10 ± 1.97 -1.71
   Sexual interest 0.97 ± 1.10 1.05 ± 1.14 0.53
   Total score 10.72 ± 7.09 9.54 ± 6.34 1.24
AUDIT score 2.28 ± 2.24 2.14 ± 2.20 1.11
Smoking (pack/years) 7.45 ± 13.51 7.01 ± 14.12 0.23
Body mass index (kg/m2) 26.90 ± 5.09 26.40 ± 4.30 0.78
Basal metabolic rate (MJ/d) 5.68 ± 0.55 5.46 ± 0.49    2.96**  
Blood pressure (mmHg)
   Systolic 143.34 ± 20.80 143.22 ± 24.13 0.04
   Diastolic 80.58 ± 8.90 79.70 ± 10.01 0.69
Waist-hip ratio 0.81 ± 0.06 0.81 ± 0.07 -0.65
**p < 0.01. ***p < 0.001.
Demographic characteristics
Table 1 displays the demographic characteristics for HRT 
users and nonusers. Independent samples t-tests showed 
that HRT users group (mean age = 61.39 years; SD = 7.98) 
was significantly younger on average and had higher mean 
basal metabolic rate than the nonusers (mean age = 66.54 
years; SD = 8.92). 
Table 2 shows that HRT users were more likely to be cur-
rently employed on a full-time basis [χ2 (df = 3, n = 213) = 
9.19, p < 0.05], and exercise more often and/or at a greater 
intensity [χ2 (df = 4, n = 209) = 11.46, p < 0.05]. Nonus-
ers were more likely to have no formal qualifications than 
users [χ2 (df = 6, n = 209) = 27.04, p < 0.001], but no clear 
pattern of differences in educational level.
WMS-III Subtests and Index Scores
After controlling for the covariates, HRT contributed 
unique variance only to the Spatial Span subtest. Overall, 
20.8% of the variance in scores on this subtest was account-
ed for by the control variables and HRT use [F (17,191) = 
2.95, p < 0.001]. At step 1, the control variables accounted 
for 19.0% of the variance in Spatial Span scores [F (16,192) 
= 2.82, p < 0.001]. At step 2, the R2 change showed that 
HRT use contributed an additional 1.8% of unique variance 
to the relationship. The partial F for HRT use produced a 
significant effect [F (1,191) = 4.33, p < 0.05]. Examination 
of the means indicated that the nonusers performed better 
on this subtest than the HRT users (Table 3). In addition 
to HRT use, age was also a significant predictor of Spatial 
Span performance at Step 2, [t (191) = -3.79, p < 0.001], 
as was education (completion of a postgraduate degree vs. 
not completion of a postgraduate degree), [t (191) = 2.52, 
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Table 2. Frequency of observations for the HRT users and nonusers on demographic and health Variables
Characteristic HRT users Nonusers
n % n %
Marital status Never married      1  1.05      3   2.54
     Married or defacto    65 68.42    75 63.56
     Separated or divorced    15 15.79      9   7.63
     Widowed    14 14.74    31 26.27
Education No formal qualifications    23 24.21    43 36.44
     Year 10 Certificate    34 35.79    36 30.51
     Year 12 Certificate      7   7.37    11   9.32
     Trade/Apprenticeship      4   4.21      1   0.85
     Certificate/Diploma    19 20.00    11   9.32
    Graduate Degree      5   5.26    10   8.47
     Postgraduate Degree      1   1.05      4   3.39
Employment status Home duties/retired    60 63.15    89 75.42
    Casual/part-time paid work    11 11.58    15 12.71
     Full-time work    22 23.16    14 11.86
     Other a      2 2.11      0   0.00
Main lifetime occupation Home duties    14 15.05    27 22.88
    Laborers and related workers      5   5.37      7   5.93
     Elementary sales/clerical/service workers      3   3.23      8   6.78
     Intermediate production/transport workers      1   1.08      0   0.00
     Intermediate clerical/sale/service workers    26 27.96    30 25.42
     Advanced clerical/service workers    10 10.75      9   7.63
     Tradespersons and related workers      7   7.53      4   3.39
     Associate professionals      8   8.60    11   9.32
     Professionals    16 17.20    20 16.95
     Managers and administrators      3   3.22      2   1.69
Socioeconomic status Secondary education, Certificate 1 or below      1   1.05      2   1.69
     Certificate 2    13 13.68    21 17.80
     Certificate 3 or 4    16 16.84    20 16.95
     Diploma or Advanced Diploma    19 20.00    27 22.88
     Bachelor Degree or higher    46 48.42    48 40.68
Annual household income ($) 0 - 19999    13 13.68      8   6.78
 20000 - 34999    13 13.68    15 12.71
35000 - 49999    11 11.58    10   8.47
50000 - $74999    21 22.11    24 20.87
75000 +    37 38.95    58 50.43
Activity level b 1      7   7.53      6   5.17
2    16 17.20    32 27.59
3    45 48.39    57 49.14
4      7   7.53      6   5.17
5    18 19.35    15 12.93
Smoking status Never smoked    56 58.95 74 62.71
Past smoker      7   7.37   6   5.08
Current smoker    32 33.68 38 32.20
Previous oral contraceptive use Yes    65 68.42    74 62.71
No    30 31.68    44 37.29
APOE allele 4 status No APOE allele 4 present    67 70.53    82 69.49
At least one APOE allele 4 present    28 29.47    36 30.51
a Includes unemployed and work without pay.  b Activity Level 1 = Moving only for necessary chores; 2 = Walking or other outdoor activities 1-2 times per week; 3 = Walking or 
other outdoor activities several times per week; 4 = Exercising 1-2 times per week to the point of perspiration; 5 = Exercising several times per week to the point of perspiration.
p < 0.05] (Table 4). The results of the one-way ANCOVA 
showed that the estrogen-only users group (M = 13.45, 
SD = 3.41) performed significantly more poorly than the 
nonusers (M = 14.19, SD = 2.89) in Spatial Span (p < 0.05). 
No other significant differences were detected among the 
three HRT groups on other WMS-III subtests.
APOE ε4 Allele Genotype
Hierarchical regressions were conducted for each WMS-III 
subtests and index scores to determine the effect of APOE 
genotype after controlling for possible influential vari-
ables. The results showed that APOE genotype contribut-
ed unique variance to scores on only the Letter-Number 
Sequencing subtest. Overall, 32.7% of the variance in scores 
on this subtest was accounted for by the control variables 
and APOE genotype F (16, 192) = 5.82, p < 0.001. At step 1, 
the control variables accounted for 30.4% of the variance 
in Letter Number Sequencing scores [F (15,193) = 5.63, 
p < 0.001]. At step 2, the R2 change showed that APOE 
genotype contributed a further 2.2% of unique variance 
to the relationship. The partial F for APOE genotype 
produced a significant effect [F (1, 192) = 6.36, p < 0.05]. 
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failure to detect a significant HRT effect has been attribut-
ed to limitations in study design and methodology [7], the 
studies that have reported beneficial effects of HRT have 
also been subject to limitations. The current investigation 
differed from these studies in a number of ways, which 
may have contributed to the dissimilar results obtained. 
The participants in the current study were all postmeno-
pausal women, while the samples in some studies were 
comprised of a mixture of perimenopausal and postmeno-
pausal women [36].  
It is possible that more positive effects of HRT on mem-
ory were observed in these studies due to higher levels of 
circulating estradiol in the perimenopausal HRT users com-
pared to postmenopausal women. Also, inclusion of peri-
menopausal women may have captured a higher proportion 
of participants in the HRT users group who had commenced 
HRT at a crucial period of endogenous estrogen depletion 
(the “critical window”), when replacement of estrogen can 
have the greatest effect on neural functioning [38, 39].
Another key difference stemmed from the statistical 
analyses conducted, particularly the rigorous control of 
possible confounding variables in the current study. Par-
ticipants in the current study were recruited via random 
sampling methods in the community, whereas some stud-
ies recruited participants via advertisement [37]. A selec-
tion bias may have been introduced by which only women 
who were concerned about their memory were included in 
the investigations in the latter study.
Estrogen-only Versus Combined Estrogen and 
Progesterone Replacement Therapy 
Estrogen-only users in this study attained a significantly 
lower score than the nonusers on Spatial Span, yet no sig-
nificant differences were found between the estrogen-on-
ly users and combined HRT users on any measures. This 
highlighted the importance of studying the effects that dif-
ferent types of HRT may have on cognitive functioning. In 
a comprehensive review of the neuropsychological effects 
of estrogen replacement by Zec and Trivedi [40], it was re-
ported that only four of the 23 observational studies and 
none of the 23 controlled trials studies compared the cog-
nitive performance of different types of HRT users.  Of the 
four observational studies that did, three found no differ-
ence in performance between estrogen-only and combined 
HRT users. On the contrary, in a study of Japanese post-
menopausal women by Rice et al. [41], women taking the 
combined form of HRT were reported to achieve signifi-
cantly lower scores on the Cognitive Abilities Screening In-
strument than the estrogen-only users.  This study, unlike 
the others, suggests that combined HRT is disadvantageous 
for cognitive functioning when compared to estrogens-on-
ly therapy. 
The superior performance of the nonusers on the Spa-
tial Span task in the current study may again be explained 
by the theory that increased levels of estrogen adversely af-
fect performance on spatial tasks, consistent with the stud-
Table 3. Means and Standard Deviations of the HRT users and 
Nonusers on the WMS-III Subtests and Index Scores
WMS-III subtest/index score
(Mean ± SD)
HRT users
(n = 95)
Nonusers
(n = 118)
Logical Memory I 36.96 ± 9.84    36.11 ± 9.67
Faces I 36.27 ± 3.54    35.12 ± 4.35
Verbal Paired Associates I 15.61 ± 6.84    14.53 ± 7.58
Family Pictures I 40.77 ± 10.43    38.16 ± 10.69
Letter-Number Sequencing 10.33 ± 2.27      9.89 ± 2.49
Spatial Span 13.73 ± 3.01    14.19 ± 2.89
Logical Memory II 21.98 ± 7.19    21.03 ± 7.82
Logical Memory II 
Recognition
25.16 ± 2.97    24.20 ± 3.18
Faces II 36.76 ± 4.08    36.40 ± 4.57
Verbal Paired Associates II 5.32 ± 2.11      5.03 ± 2.34
Verbal Paired Associates II 
Recognition
23.98 ± 0.14    23.81 ± 0.71
Family Pictures II 40.68 ± 10.67    37.42 ± 10.92
Auditory Immediate Index 100.79 ± 13.95  101.01 ± 15.68
Visual Immediate Index 104.03 ± 12.95  102.70 ± 13.81
Immediate Memory Index 102.74 ± 12.82  102.24 ± 15.62
Auditory Delayed Index 104.69 ± 12.69  105.20 ± 15.28
Auditory Delayed 
Recognition Index
106.05 ± 15.44  102.58 ± 13.91
Visual Delayed Index 107.35 ± 14.32  107.08 ± 14.22
General Memory Index 107.32 ± 13.88  106.60 ± 15.31
Working Memory Index 102.69 ± 12.37  104.98 ± 12.24
Inspection of the means indicated the APOE ε4 allele 
bearers (M = 10.55, SD = 2.33) performed better on this 
test than the nonbearers (M = 9.89, SD = 2.41). In addition 
to APOE genotype, two other variables were significant 
predictors of Letter-Number Sequencing performance: 
age t(192) = -5.55, p < 0.001, and NART predicted FSIQ 
t(192) = 4.41, p < .001 (Table 5). However, power to detect 
significant effects was slightly reduced in these regression 
analyses, as a sample size of 67 in each group is required to 
obtain a medium effect size [32]. The results of the two-by-
two ANCOVAs found not significant main effect of HRT 
across any of the WMS-III performance scores. There was 
no significant main effect of APOE genotype on WMS-
III performance apart from Letter Number Sequencing, 
similar to the finding from the regression.
Discussion
The Effects of HRT on Memory Functioning
The current results demonstrated only very minimal sup-
port for HRT having a beneficial effect on memory func-
tioning, particularly verbal memory. Across all subtests of 
the WMS-III, HRT was found to adversely affect perfor-
mance on the Spatial Span subtest of the WMS-III. The 
overall lack of significant effects of HRT on memory perfor-
mance is generally consistent with the findings of previous 
observational studies showing that HRT has no influence 
on cognitive functioning [e.g. 10, 34] and randomized-con-
trolled trials [e.g. 9, 35]. However, the findings are contrary 
to studies of equivalent quality that have demonstrated ben-
eficial effects of HRT on cognition [e.g. 36, 37]. While the 
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Table 4. Unstandardized regression coefficients (B), standard error of the unstandardized regression coefficients (SE 
B), and standardized regression coefficients (β) for the relationship between the control variables, HRT use, and Spatial 
Span scores. 
Variable B SE B β
Step 1
    Age     -0.08     0.02    -0.24**
    Education [No formal qualifications]
        Year 10 v not Year 10     -0.18     0.54    -0.03
        Year 12 v not Year 12     -0.76     0.86    -0.07
        Trade/Apprentice v not Trade/Apprentice      0.46     1.30     0.02
        Certificate/Diploma v not Certificate/Diploma      1.12     0.74     0.13
        Graduate Degree v not Graduate Degree      1.43     0.96     0.13
Postgraduate Degree v not Postgraduate Degree      3.99     1.44     0.21**
   NART predicted FSIQ      0.04     0.02     0.12
   SES rankinga [1]
        2      0.18     1.71     0.02
        3      0.18     1.70     0.02
        4      0.13     1.68     0.02
        5      0.03     1.70     0.01
   GCS score     -0.01     0.03    -0.03
   GHQ-30 score     -0.05     0.05    -0.07
   APOE genotype classification     -0.24     0.43    -0.04
   Use of psychiatric medications     -0.69     0.54    -0.09
Step 2
   Age     -0.09     0.03    -0.29***
   Education [No formal qualifications]
        Year 10 v not Year 10     -0.16     0.54    -0.03
        Year 12 v not Year 12     -0.94     0.85    -0.09
        Trade/Apprentice v not Trade/Apprentice      0.81     1.30     0.04
        Certificate/Diploma v not Certificate/Diploma      1.14     0.74     0.14
        Graduate Degree v not Graduate Degree      1.15     0.96     0.10
        Postgraduate Degree v not Postgraduate Degree      3.63     1.44     0.19*
   NART predicted FSIQ      0.04     0.02     0.14
   SES ranking a [1]
         2      0.23     1.70     0.03
         3      0.27     1.67     0.04
         4      0.21     1.67     0.03
         5      0.18     1.69     0.03
   GCS score     -0.01     0.03    -0.03
   GHQ-30 score     -0.04     0.05    -0.07
   APOE genotype classification     -0.21     0.43    -0.03
   Use of psychiatric medication     -0.50     0.54    -0.06
   HRT use     -0.87     0.42     0.15*
a 1 = Reference category of Secondary education, Certificate 1, or below; 2 = Certificate 2 v not Certificate 2; 3 = Certificate 3 or 4 v not Certificate 3 or 4; 
4 = Diploma or Advanced Diploma v not Diploma or Advanced Diploma; 5 = Bachelor Degree or higher v not Bachelor Degree or higher.
* p < .05. ** p < .01. ***p < .001.
ies showing that spatial task performance across the phases 
of the menstrual cycle is better when estradiol levels are low 
[42, 43]. The current findings indicate that when estrogen 
is combined with progesterone, this detrimental effect is 
not observed. Progesterone has also been reported to de-
crease the activity of excitatory neurotransmitters [44]. It is 
unclear what specific effects progesterone has on neuronal 
function in postmenopausal women, although it has been 
suggested that this hormone may be associated with dif-
ferent cognitive performance than that which is observed 
with estrogen therapy alone [7, 44].  It is possible that pro-
gesterone may counteract the adverse effects that estrogen 
may have on spatial task performance, thus explaining the 
current findings.
The Effects of APOE Genotype and HRT on Memory 
Functioning
In the current studies, having the APOE ε4 was found to 
contribute unique variance to better performance on the 
Letter-Number Sequencing subtest for the WMS-III. This 
is generally consistent with studies that have reported no 
relationship between APOE genotype and cognitive func-
tioning [e.g. 45] but contradicts studies that have demon-
strated an increased risk of cognitive decline [e.g. 15]. The 
inconsistent findings may be due to the fact that the associ-
ation between APOE genotype and neurological function-
ing is fairly complex, and simply comparing ε4 bearers and 
nonbearers may not entirely capture the differential effects 
that the genotype combinations may have on cognitive 
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Table 5. Unstandardized regression coefficients (B), standard error of the unstandardized regression coefficients (SE 
B), and standardized regression coefficients (β) for the relationship between the control variables, APOE genotype, 
and Letter-Number Sequencing Span scores.
Variable B SE B β
Step 1
    Age     -0.10     0.02    -0.37***
    Education [No formal qualifications]         -        -        -
        Year 10 v not Year 10      0.34     0.41     0.67
        Year 12 v not Year 12     -0.20     0.65    -0.02
        Trade/Apprentice v not Trade/Apprentice     -0.12     0.98    -0.01
        Certificate/Diploma v not Certificate/Diploma     -0.34     0.56    -0.05
        Graduate Degree v not Graduate Degree      0.19     0.73     0.02
        Postgraduate Degree v not Postgraduate Degree      0.64     1.08     0.04
  NART predicted FSIQ      0.07     0.02     0.30***
  SES rankinga [1]     -0.15     0.13    -0.08
         2      0.73     1.23     0.11
         3     -0.11     1.29    -0.02
         4     -0.36     1.27    -0.06
         5      0.50     1.29     0.10
 GCS score      0.01     0.03     0.02
 GHQ-30 score     -0.06     0.04    -0.11
 Use of psychiatric medications     -0.19     0.41    -0.03
Step 2
   Age    -0.10     0.02    -0.37***
   Education [No formal qualifications]        -       -        -
        Year 10 v not /Year 10     0.32     0.40     0.06
        Year 12 v not Year 12    -0.38     0.64    -0.04
        Trade/Apprentice v not Trade/Apprentice    -0.00     0.97    -0.00
        Certificate/Diploma v not Certificate/Diploma    -0.32     0.56    -0.05
        Graduate Degree v not Graduate/Degree     0.01     0.72     0.01
        Postgraduate Degree v not Postgraduate Degree     0.27     1.08     0.02
   NART predicted FSIQ     0.01     0.02     0.33***
   SES ranking a [1]       -       -        -
         2     0.62     1.28     0.10
         3    -0.36     1.27    -0.06
         4    -0.57     1.26    -0.10
         5     0.29     1.27     0.06
   GCS score     0.01     0.03     0.03
   GHQ-30 score    -0.01     0.04    -0.11
   Use of psychiatric medications    -0.16     0.40    -0.02
   APOE genotype classification     0.81     0.32     0.16*
a 1 = Reference category of Secondary education, Certificate 1, or Below; 2 = Certificate 2 v not Certificate 2, 3 = Certificate 3 or 4 v not Certificate 3 or 4; 
4 =  Diploma or Advanced Diploma v not Diploma or Advanced Diploma, 5 = Bachelor Degree or higher v not Bachelor Degree or higher.
*p < .05. *** p < .001.
functioning. For example, the ε2 allele has been found to 
be slightly under-represented in patients with Alzheimer’s 
Disease (AD) and thus it may confer a protective effect [46]. 
However, this allele has also been associated with increased 
risk of cerebrovascular disease [e.g. 47], though this is a 
point of controversy [e.g. 48], and so cognitive impairment 
resulting from vascular disease may be more prevalent in ε2 
bearers. Additionally, the age of onset of AD is dose-depen-
dent, such that bearers of two ε4 alleles tend to develop AD 
at a younger age than bearers of one ε4 allele [49].  Careful 
consideration of the genotype combinations is therefore re-
quired in order to fully assess their influence on cognition. 
Additional analyses were performed and no interac-
tions were found between HRT and APOE genotype in the 
current study, indicating that the APOE genotype did not 
change the association between HRT use and performance 
on the WMS-III. This was consistent with the findings of 
Jacobs et al. [21], who reported no relationship between es-
trogen replacement and APOE genotype. In contrast, Yaffe 
et al. [50] reported that postmenopausal non-ε4 bearers 
who were current estrogen users demonstrated significant-
ly less cognitive decline over a five to seven year period on 
the Modified Mini Mental State Examination than women 
who were never or past users. However, the estrogen us-
ers who were ε4 bearers did not demonstrate less cognitive 
decline than the never or past users. Similarly, Burkhardt et 
al. [23] reported that estrogen-only users who were non-ε4 
bearers performed best on a test of episodic learning and 
memory, with no beneficial effects on performance report-
ed for the estrogen-only users who were ε4 bearers.  
It is difficult to reconcile the current findings with those 
of the previous investigations, given the many differences 
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in study design and methodology. However, one notewor-
thy feature of the current study that may have contribut-
ed to the finding of no interaction between HRT use and 
APOE genotype is the high proportion of HRT users in the 
current study using medroxyprogesterone acetate (MPA). 
As noted previously, there is evidence to indicate that this 
progesterone antagonizes the beneficial effects of estrogen 
on cognitive functioning [38]. In the aforementioned stud-
ies by Burkhardt et al. [23] and Yaffe et al. [50] , in which 
the ε4 allele was found to modify the association between 
estrogen-only therapy and cognitive performance, only 
women using estrogen-only therapy were included. In in-
vestigating the relationship between HRT and the APOE 
genotype in the current studies, it would have been prefer-
able to perform separate analyses of the estrogen-only us-
ers (who did not use MPA) and examine the performance 
of those with and without the ε4 allele. However, due to 
the sample size, there was not sufficient power to investi-
gate the estrogen-only users in the analyses while also tak-
ing their genotype into consideration. 
Conclusions
In summary, HRT use was observed to have minimum ef-
fect overall on the performance of postmenopausal women 
on the WMS-III. The APOE ε4 allele was also demonstrat-
ed to have minimal influence on cognitive functioning, 
and it did not interact significantly with HRT to affect test 
performance. While the current studies addressed many 
of the limitations of previous research, additional im-
provements in study methodology may assist in furthering 
the understanding of the relationship between HRT and 
memory functioning, and the influence of APOE geno-
type. It is possible that other factors, such as cumulative 
lifetime exposure to estrogens, including pregnancies and 
the use of oral contraceptives, the length of the period be-
fore menopausal women begin HRT, as well as psycholog-
ical variables, may have a broader influence on memory 
performance in this cohort of women.
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